OptiScan Biomedical

OptiScan Biomedical Corporation has developed an innovative monitoring platform for use in hospital intensive care units (ICU) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention. The OptiScanner® platform is presently focused on delivering automated bedside glucose monitoring to support clinicians’ reach and maintain the right level of glucose control.

Hayward, US
50 (est)

Key People at OptiScan Biomedical

Monnett Soldo

Monnett Soldo

Vice President of Research and Development
Peter R. Rule

Peter R. Rule

Chairman of the Board
Donald J. Webber

Donald J. Webber

Chief Operating Officer

OptiScan Biomedical Locations

Hayward, US

OptiScan Biomedical Metrics

OptiScan Biomedical Summary

Founding Date


Total Funding

$130 M

Latest funding size

$29.5 M

Time since last funding

5 months